Christopher L. Corless
Oregon Health & Science University · 516 works · 51,747 citations · h-index 101
Top works
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
- Diagnosis of gastrointestinal stromal tumors: A consensus approach
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
- Use of Colonoscopy to Screen Asymptomatic Adults for Colorectal Cancer
- PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
- Biology of Gastrointestinal Stromal Tumors
- One-Time Screening for Colorectal Cancer with Combined Fecal Occult-Blood Testing and Examination of the Distal Colon
- Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis.
- KIT Mutations Are Common in Incidental Gastrointestinal Stromal Tumors One Centimeter or Less in Size
- Gastrointestinal stromal tumour
- Papillary (Chromophil) Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic Prognostic Parameters in 62 Cases
- PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
- Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues.
- The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status
- A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells
- NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- Gastrointestinal stromal tumours: origin and molecular oncology